Skip to content
BiologicalX

Comparison

GHK-Cu vs Methylene Blue

Side-by-side of GHK-Cu and Methylene Blue. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.

Effects at a glance

GHK-Cu

  • Endogenous tripeptide that binds copper(II); plasma levels decline ~60% from age 20 to 60
  • Topical RCTs show improvement in skin firmness, fine lines, and barrier function over 12 weeks
  • Wound-healing models report accelerated re-epithelialization in diabetic and aged skin
  • Pickart gene-expression analyses show reset of >4000 genes toward a younger expression profile in cell culture
  • Anecdotal subcutaneous longevity protocols use 1 to 3 mg daily; no human longevity RCTs exist
  • Hair-growth claims rest on small open-label trials and topical scalp formulations

Methylene Blue

  • FDA approved for methemoglobinemia and ifosfamide-induced encephalopathy
  • Mitochondrial electron-transport support at low doses (0.5 to 4 mg/kg) via cytochrome c shuttle
  • Potent MAO-A inhibitor; serotonin syndrome risk with SSRIs, SNRIs, MAOIs, fentanyl, tramadol, St John's wort
  • Causes harmless blue-green urine and sweat coloration; useful adherence marker
  • G6PD deficiency is an absolute contraindication; can trigger massive hemolysis
  • Cognitive-enhancement evidence is preliminary, mostly preclinical and small fMRI trials

Side-by-side

Attribute GHK-Cu Methylene Blue
Category peptide pharmaceutical
Also known as Copper Peptide, Glycyl-L-histidyl-L-lysine copper, GHK Methylthioninium chloride, Provayblue, tetramethylthionine chloride
Half-life (hr) 0.5 5.5
Typical dose (mg) 2 70
Dosing frequency daily 1 to 3 times daily for cognitive use; single IV dose for methemoglobinemia
Routes topical, subcutaneous oral, intravenous
Onset (hr) 24 1
Peak (hr) 168 1.5
Molecular weight 340.85 319.85
Molecular formula C14H24N6O4 (GHK alone); C14H22CuN6O4 with Cu(II) C16H18ClN3S
Mechanism Tripeptide that chelates Cu(II) and delivers it to copper-dependent enzymes (lysyl oxidase, superoxide dismutase). Modulates expression of >4000 genes toward a younger profile in fibroblast culture, including upregulation of decorin and downregulation of pro-inflammatory cytokines. Mitochondrial electron carrier at low doses (cytochrome c shuttle to complex IV) and methemoglobin reductase substrate at higher doses; potent MAO-A inhibitor across the dose range.
Legal status Topical cosmetics legal in most jurisdictions; injectable form not FDA approved for any indication; research-use-only grey market Prescription (injectable, FDA approved); supplement form (oral) widely available; not scheduled
WADA status allowed allowed
DEA / Rx Topical OTC (cosmetic); injectable not FDA approved; research-chemical status Not scheduled in the US
Pregnancy Insufficient data; topical use likely low-risk; injectable not recommended Contraindicated
CAS 49557-75-7 61-73-4
PubChem CID 73587 6099
Wikidata Q3104638 Q409021

Safety profile

GHK-Cu

Common side effects

  • mild erythema at topical site
  • transient itch
  • blue-green discoloration of injection site (copper)
  • rare contact dermatitis

Contraindications

  • copper allergy
  • Wilson disease
  • open wound near injection site (caution)
  • pregnancy (no data)

Interactions

  • topical retinoids: additive irritation; alternate days or apply at different times(minor)
  • topical vitamin C (ascorbic acid): ascorbate reduces Cu(II) to Cu(I), which can destabilize the GHK-Cu complex; separate by 30 minutes(minor)

Methylene Blue

Common side effects

  • blue-green urine and sweat
  • skin and oral mucosa staining
  • GI upset
  • headache
  • dizziness

Contraindications

  • G6PD deficiency
  • pregnancy
  • concurrent serotonergic medication
  • severe renal impairment
  • infants under 6 months

Interactions

  • SSRIs and SNRIs: serotonin syndrome, potentially fatal(major)
  • MAOIs: additive MAO inhibition, serotonin syndrome risk(major)
  • fentanyl, tramadol, meperidine: serotonin syndrome risk(major)
  • dextromethorphan: serotonin syndrome risk(major)
  • St John's wort: serotonin syndrome risk(major)
  • lithium: additive serotonergic risk(major)

Which Should You Take?

Methylene Blue comes out ahead for most readers on the criteria we weight: 3 catalogued goals, controlled substance, oral dosing, with a Tier-A outcome catalogued. GHK-Cu is the right call when one of the conditionals below applies.

  • If your priority is skin health, pick GHK-Cu.
  • If your priority is wound healing, pick GHK-Cu.
  • If your priority is focus or working memory, pick Methylene Blue.
  • If your priority is mitochondrial function, pick Methylene Blue.

Edge case: If you cannot self-administer injections, Methylene Blue is the only oral option in this pair.

Default choice: Methylene Blue. Wider use case, a Tier-A evidence outcome catalogued, and broader goal coverage. Reach for GHK-Cu only if your priority sits squarely in the goals it owns above.

This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.

Common questions

What is the difference between GHK-Cu and Methylene Blue?

GHK-Cu and Methylene Blue differ in category (peptide vs pharmaceutical), mechanism, and typical dosing. See the side-by-side table for full details.

Which has a longer half-life, GHK-Cu or Methylene Blue?

GHK-Cu half-life is 0.5 hours; Methylene Blue half-life is 5.5 hours.

Can you stack GHK-Cu with Methylene Blue?

Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.

Go deeper